Introduction: Atypical antipsychotics can affect cortical volume differently from traditional drugs. The study of the outcome of grey matter deficits in schizophrenia with olanzapine may be of particular interest in this context.
Methods: In this study, we evaluated the changes in the volume of gray matter in the cortex of 11 schizophrenic patients treated with olanzapine and in 11 healthy controls after three years of follow-up. After MR imaging, acquisition data were processed with a volumetric quantification method based on the Talairach atlas. The longitudinal change of volumetric data was corrected for differences in overall brain size.
Results: Patients showed greater reduction than controls in cortical volume in the frontal and parietal regions during follow-up. No relationship was observed between clinical and volumetric changes.
Conclusion: Our data suggest that the profile of action of olanzapine on the cortical volume of chronically ill patients may be similar to that of typical antipsychotics. Other explanations, however, cannot be completely discarded for that outcome with our data.
References
1
Andreasen NC, Rajarethinam R, Cizadlo T, Arndt S, Swayze 2nd VW, Flashman LA, O’Leary DS, Ehrhardt JC, Yuh WT.
Automatic atlas-based volume estimation of human brain regions from MR images.
J Comput Assist Tomogr.
1996;
20
98-106
4
Bartzokis G, Beckson M, Lu PH, Nuechterlein KH, Edwards N, Mintz J.
Age-related changes in frontal and temporal lobe volumes in men: a magnetic resonance imaging study.
Arch Gen Psychiatry.
2001;
58
461-465
5
Chard DT, Parker GJ, Griffin CM, Thompson AJ, Miller DH.
The reproducibility and sensitivity of brain tissue volume measurements derived from an SPM-based segmentation methodology.
J Magn Reson Imaging.
2002;
15
259-567
6
Coffey CE, Wilkinson WE, Parashos IA, Soady SA, Sullivan RJ, Patterson LJ, Figiel GS, Webb MC, Spritzer CE, Djang WT.
Quantitative cerebral anatomy of the aging human brain: a cross-sectional study using magnetic resonance imaging.
Neurology.
1992;
42
527-536
10
Gispert JD, Reig S, Pascau J, Vaquero JJ, Desco M.
Repeatability of brain tissue volume quantification using magnetic resonance images. 10th Annual Meeting of the Organization for Human Brain Mapping, Budapest, Hungary.
Neuroimage.
2004;
22
((suppl 1))
11
Gur RE, Cowell P, Turetsky BI, Gallacher F, Cannon T, Bilker W, Gur RC.
A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures.
Arch Gen Psychiatry.
1998;
55
145-152
12
Ho BC, Andreasen NC, Nopoulos P, Arndt S, Magnotta V, Flaum M.
Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia.
Arch Gen Psychiatry.
2003;
60
585-594
15
Katsel P, Davis KL, Haroutunian V.
Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: A gene ontology study.
Schizophr Res.
2005;
79
157-173
17
Keshavan MS, Haas GL, Kahn CE, Aguilar E, Dick EL, Schooler NR, Sweeney JA, Pettegrew JW.
Superior temporal gyrus and the course of early schizophrenia: progressive, static, or reversible?.
J Psychiatr Res.
1998;
32
161-167
18
Lambert M, Conus P, Schimmelmann BG, Eide P, Ward J, Yuen H, Schacht M, Edwards J, Naber D, McGorry PD.
Comparison of olanzapine and risperidone in 367 first-episode patients with non-affective or affective psychosis: results of an open retrospective medical record study.
Pharmacopsychiatry.
2005;
38
206-213
19
Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, Keefe RS, Green AI, Gur RE, McEvoy J, Perkins D, Hamer RM, Gu H, Tohen M.
Antipsychotic drug effects on brain morphology in first-episode psychosis.
Arch Gen Psychiatry.
2005;
62
361-370
20
Mathalon DH, Sullivan EV, Lim KO, Pfefferbaum A.
Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study.
Arch Gen Psychiatry.
2001;
58
148-157
21
McCormick L, Decker L, Nopoulos P, Ho BC, Andreasen N.
Effects of atypical and typical neuroleptics on anterior cingulate volume in schizophrenia.
Schizophr Res.
2005;
80
73-84
25
Molina V, Reig S, Sanz J, Palomo T, Benito C, Sánchez J, Sarramea F, Pascau J, Desco M.
Increase in gray matter volume and decrease in white matter volume in the cerebral cortex during treatment with atypical neuroleptics in schizophrenia.
Schizophrenia Res.
2005;
80
61-71
28
Pfefferbaum A, Lim KO, Zipursky RB, Mathalon DH, Rosenbloom MJ, Lane B, Ha CN, Sullivan EV.
Brain gray and white matter volume loss accelerates with aging in chronic alcoholics: a quantitative MRI study.
Alcohol Clin Exp Res.
1992;
16
1078-1089
31
Selemon LD, Rajkowska G.
Goldman-Rakic PS Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17.
Arch Gen Psychiatry.
1995;
52
805-818
32
Selemon LD, Rajkowska G.
Goldman-Rakic PS Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: application of a three-dimensional, stereologic counting method.
J Comp Neurol.
1998;
392
402-412
33
Sowell ER, Peterson BS, Thompson PM, Welcome SE, Henkenius AL, Toga AW.
Mapping cortical change across the human life span.
Nat Neurosci.
2003;
6
309-315
34
Stark AK, Uylings HB, Sanz-Arigita E, Pakkenberg B.
Glial cell loss in the anterior cingulate cortex, a subregion of the prefrontal cortex, in subjects with schizophrenia.
Am J Psychiatry.
2004;
161
882-888
35
Szulc A, Galinska B, Tarasow E, Dzienis W, Kubas B, Konarzewska B, Walecki J, Alathiaki AS, Czernikiewicz A.
The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1 H MRS).
Pharmacopsychiatry.
2005;
38
214-219
37
Uranova NA, Vostrikov VM, Orlovskaya DD, Rachmanova VI.
Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium.
Schizophr Res.
2004;
67
269-275
